Literature DB >> 7814374

Characterization of an autoinhibitory domain in human mitogen-activated protein kinase-activated protein kinase 2.

Y L Zu1, Y Ai, C K Huang.   

Abstract

Mitogen-activated protein (MAP) kinase-activated protein kinase 2, a Ser/Thr kinase, is phosphorylated and activated by MAP kinase. Sequence analysis of a clone isolated from the human HL-60 cell line revealed a 370-amino acid protein with a proline-rich N terminus, a highly conserved catalytic domain, and a C-terminal region containing a MAP kinase phosphorylation site. To better understand how the kinase is regulated, mutation analysis was used to map the functional domain(s). The wild type recombinant kinase had a low basal activity as detected by phosphorylation of a substrate peptide derived from the N terminus of glycogen synthase. Deletion of the proline-rich N terminus showed little effect on the basal activity. Deletion of the C terminus resulted in a marked increase in catalytic activity either with or without the pretreatment of the kinase by MAP kinase. Further analysis indicated that amino acid residues 339-353 in the C-terminal region were acting as an autoinhibitory domain. A synthetic peptide (RVLKEDKERWEDVK-amide) derived from this autoinhibitory domain inhibited the kinase activity in a concentration-dependent manner. These results suggest a regulatory model for the kinase.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7814374     DOI: 10.1074/jbc.270.1.202

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Autoinhibitory regulation of TrwK, an essential VirB4 ATPase in type IV secretion systems.

Authors:  Alejandro Peña; Jorge Ripoll-Rozada; Sandra Zunzunegui; Elena Cabezón; Fernando de la Cruz; Ignacio Arechaga
Journal:  J Biol Chem       Date:  2011-03-24       Impact factor: 5.157

2.  Characterization of a novel MK3 splice variant from murine ventricular myocardium.

Authors:  Nadège Moïse; Dharmendra Dingar; Aida M Mamarbachi; Louis R Villeneuve; Nada Farhat; Matthias Gaestel; Maya Khairallah; Bruce G Allen
Journal:  Cell Signal       Date:  2010-06-04       Impact factor: 4.315

3.  FRET-based detection of different conformations of MK2.

Authors:  A Neininger; H Thielemann; M Gaestel
Journal:  EMBO Rep       Date:  2001-07-19       Impact factor: 8.807

4.  Discovery and Hit-to-Lead Optimization of Non-ATP Competitive MK2 (MAPKAPK2) Inhibitors.

Authors:  Xiaohua Huang; Gerald W Shipps; Cliff C Cheng; Peter Spacciapoli; Xingmin Zhang; Mark A McCoy; Daniel F Wyss; Xianshu Yang; Abdelghani Achab; Kyle Soucy; Donna K Montavon; Denise M Murphy; Charles E Whitehurst
Journal:  ACS Med Chem Lett       Date:  2011-06-24       Impact factor: 4.345

Review 5.  Heat shock protein 27 phosphorylation: kinases, phosphatases, functions and pathology.

Authors:  Sergiy Kostenko; Ugo Moens
Journal:  Cell Mol Life Sci       Date:  2009-07-11       Impact factor: 9.261

6.  Mitogen-activated protein kinase-activated protein kinase-2 (MK2) and its role in cell survival, inflammatory signaling, and migration in promoting cancer.

Authors:  Deri Morgan; Kiersten L Berggren; Colby D Spiess; Hannah M Smith; Ajay Tejwani; Scott J Weir; Christopher E Lominska; Sufi M Thomas; Gregory N Gan
Journal:  Mol Carcinog       Date:  2021-09-24       Impact factor: 4.784

7.  Molecular basis of MAPK-activated protein kinase 2:p38 assembly.

Authors:  Andre White; Christopher A Pargellis; Joey M Studts; Brian G Werneburg; Bennett T Farmer
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-29       Impact factor: 11.205

Review 8.  Targeting Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MAPKAPK2, MK2): Medicinal Chemistry Efforts To Lead Small Molecule Inhibitors to Clinical Trials.

Authors:  Mario Fiore; Stefano Forli; Fabrizio Manetti
Journal:  J Med Chem       Date:  2015-11-09       Impact factor: 7.446

9.  Integrative bioinformatics analysis of KPNA2 in six major human cancers.

Authors:  Chaobo Xu; Ming Liu
Journal:  Open Med (Wars)       Date:  2021-03-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.